Mass Spectrometry Takes on Amyloid  - Summary - MDSpire

Mass Spectrometry Takes on Amyloid 

New guidelines target false negatives, Congo red variability, and the growing role of mass spectrometry in amyloid typing

  • February 18, 2026

  • 9 min

Share

Objective:

To standardize amyloidosis diagnostics, ensuring timely treatment through improved detection methods.

Key Findings:
  • Standardized protocols are essential for reliable amyloid detection, impacting treatment outcomes.
  • Fat pad FNA is valuable but has limitations in sensitivity and specificity that must be considered.
  • Mass spectrometry offers superior accuracy for amyloid typing compared to immunohistochemistry, influencing clinical decisions.
Interpretation:

The updated guidelines emphasize standardized practices in amyloid diagnostics to reduce variability and enhance patient outcomes.

Limitations:
  • Sensitivity of fat pad FNA varies by amyloid type, affecting diagnostic reliability.
  • False negatives and positives in staining techniques can lead to misdiagnosis.
  • IHC-based typing may yield incorrect results, complicating clinical management.
Conclusion:

The shift towards mass spectrometry and standardized protocols marks a significant advancement in the accurate diagnosis of amyloidosis.

Original Source(s)

Mass Spectrometry Takes on Amyloid 

  • February 18, 2026

Related Content

Combined Clavicle Model May Improve Age Estimates

Combined approach shows higher sensitivity than traditional thresholds for classifying legal adulthood.

Automated Staining Aids Real-Time Tumor Calls

Automated frozen-section staining helped classify selected ambiguous tumors and margins in a single-center validation study.

Prototype Mass Spectrometer Handles Billions of Ions at Once

Nature-inspired prototype points toward faster, more sensitive single-cell proteomics and metabolomics

  • April 9, 2026

  • 2 min